Drug Discovery Services Market by Process (Target Validation, Hit-to-Lead, Lead Optimization), Type (Chemistry, Biology), Therapeutic Area (Oncology, Neurology, Infectious, CVD), Drug Type (Small Molecules, Biologics), End User - Global Forecast to 2030
세계의 Drug Discovery 서비스 시장 규모는 2025년 163억 6,000만 달러에서 2030년에는 272억 3,000만 달러에 달할 것으로 예측되며, CAGR은 10.7%로 현저하게 확대할 것으로 보이고 있습니다.
이 시장은 제약 및 바이오 제약 기업의 R&D 투자 증가로 인해 상당한 CAGR로 강력하게 성장하고 있습니다. R&D 파이프라인이 확대됨에 따라 희귀질환 및 희귀의약품에 대한 연구 구상과 더불어 분석 시험 아웃소싱에 대한 요구가 증가하고 있습니다. 또한 자체적으로 의약품을 개발하는 데 드는 높은 비용도 이러한 추세에 박차를 가하고 있습니다. 업계 업체들은 기술 발전, 신약 개발, 특허 만료, 최종사용자의 전문 검사 서비스에 대한 수요 증가로 인해 건전한 성장 기회를 목격할 수 있을 것으로 보입니다.
| 조사 범위 |
| 조사 대상 연도 |
2024-2030년 |
| 기준연도 |
2024년 |
| 예측 기간 |
2024-2030년 |
| 검토 단위 |
금액(10억 달러) |
| 부문 |
프로세스별, 유형별, 치료 영역별, 약제 유형별, 최종사용자별, 지역 |
| 대상 지역 |
북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카 |
유형별로 보면 신약개발 서비스 시장은 화학 서비스와 생물학 서비스로 나뉩니다. 화학 서비스는 다시 합성 화학 서비스, 분석 화학 서비스, 기타 화학 서비스로 나뉩니다. 조합 화학 및 구조 기반 약물 설계와 같은 기술 개발이 화학 서비스의 성장에 기여하고 있습니다. 특히 신약개발에서 리드분자의 식별, 리드분자의 변형 및 최적화, 최적화된 리드분자의 추가 의약품 개발 프로세스로의 스케일업, 유효성 시험 등 화학이 광범위하게 활용되고 있는 것이 이 분야 수요 증가에 기여하고 있습니다.
프로세스별로 살펴보면, 신약개발 서비스 시장에는 표적 선택, 표적 검증, 히트 투 리드 식별, 리드 최적화, 후보물질 검증이 포함됩니다. 이 중 히트-투-리드 식별 서비스가 시장을 독점하고 있습니다. 신약개발에서 중요한 위치를 차지하고 있고, 가장 큰 매출을 창출하는 과정이기 때문에 히트-투-리드 식별 서비스 시장의 성장은 이미 정해져 있습니다. 많은 CRO들이 제약회사에 이러한 서비스를 제공합니다. 또한 주요 기업은 신약 개발의 이 중요한 단계를 개선하는 데 주력하고 있습니다.
신약개발 서비스 시장은 약물의 유형에 따라 저분자와 생물제제로 구분됩니다. 저분자가 시장에서 가장 큰 비중을 차지할 것으로 예상됩니다. 저분자의 성장이 확대되고 있는 배경에는 작업의 용이성, 낮은 비용, 저분자 의약품 개발에 집중하는 스타트업 및 신규 진출기업이 증가하고 있는 점 등이 있습니다. 저분자는 분자량이 작기 때문에 세포 내로 쉽게 들어갈 수 있습니다. 저분자는 다른 분자에 작용하여 암세포를 사멸시킬 수 있습니다. 따라서 저분자 또는 저분자 억제제는 많은 표적치료에 널리 사용되고 있습니다.
치료 영역 부문은 암, 감염성 질환, 심혈관 질환, 신경질환, 면역 질환, 내분비 및 대사 질환, 호흡기 질환, 소화기 질환, 비뇨생식기 질환 및 여성 건강, 기타 치료 영역으로 나뉩니다. 심혈관 질환 시장은 심혈관 질환의 높은 유병률, 노인 인구 증가, CRO와 제약 및 생명공학 기업과의 파트너십 증가로 인해 우위를 점하고 있습니다. 유전자와 맞춤형 의료의 혁신의 통합도 심혈관 질환 치료제의 발견과 개발의 성장을 지원할 것으로 보입니다.
최종사용자별로 시장은 제약 및 바이오테크놀러지 기업, 학술기관, 기타 최종사용자로 구분되며, 2024년에는 제약 및 바이오테크놀러지 기업이 시장을 주도할 것으로 예상됩니다. 제약 및 생명공학 기업이 신약개발 서비스 시장에서 가장 높은 점유율을 차지하는 이유는 신물질 개발을 위한 R&D 비용 증가, 이들 기업의 임상 서비스 아웃소싱 증가, 이익률 향상과 신약 개발 기간 단축을 위한 생명공학 기업의 강력한 파이프라인 때문입니다.
지역별로는 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카로 구분됩니다. 북미는 2024년 신약개발 서비스 시장을 장악할 것으로 예상되며, 예측 기간 중에도 지배력을 유지할 것으로 예상됩니다. 미국은 주요 진입기업의 존재로 인해 북미 시장을 주도하고 있습니다. 미국은 R&D 비용에 집중하고 있으며, 바이오시밀러 및 바이오의약품 시장의 급격한 성장으로 인해 시장 주도권을 더욱 강화할 것으로 예상됩니다. 유럽의 신약개발 서비스 시장은 인구통계학적 변화, 질병 확산, R&D 투자에 힘입어 꾸준한 성장세를 보이고 있습니다.
세계의 Drug Discovery 서비스 시장에 대해 조사했으며, 프로세스별, 유형별, 치료 영역별, 약제 유형별, 최종사용자별, 지역별 동향 및 시장에 참여하는 기업의 개요 등을 정리하여 전해드립니다.
목차
제1장 서론
제2장 조사 방법
제3장 개요
제4장 주요 인사이트
제5장 시장 개요
- 서론
- 시장 역학
- 고객 비즈니스에 영향을 미치는 동향/혼란
- 가격 분석
- 공급망 분석
- 밸류체인 분석
- 에코시스템 분석
- 투자와 자금조달 시나리오
- 기술 분석
- 특허 분석
- 2025-2026년의 주요 컨퍼런스와 이벤트
- 규제 상황
- Porter's Five Forces 분석
- 주요 이해관계자와 구입 기준
- AI가 Drug Discovery 서비스 시장에 미치는 영향
제6장 Drug Discovery 서비스 시장(프로세스별)
- 서론
- 표적 선택
- 표적 검증
- HIT-TO-LEAD 식별
- 리드 최적화
- 후보의약품 검증
제7장 Drug Discovery 서비스 시장(유형별)
제8장 Drug Discovery 서비스 시장(약제 유형별)
제9장 Drug Discovery 서비스 시장(치료 영역별)
- 서론
- 종양
- 감염증
- 심혈관질환
- 신경질환
- 면역 질환
- 내분비 및 대사장애
- 호흡기질환
- 소화기 질환
- 비뇨기 질환과 부인과 질환
- 기타
제10장 Drug Discovery 서비스 시장(최종사용자별)
- 서론
- 제약·바이오테크놀러지 기업
- 학술기관
- 기타
제11장 Drug Discovery 서비스 시장(지역별)
- 서론
- 북미
- 유럽
- 유럽의 거시경제 전망
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 기타
- 아시아태평양
- 아시아태평양의 거시경제 전망
- 중국
- 일본
- 인도
- 한국
- 호주
- 기타
- 라틴아메리카
- 라틴아메리카의 거시경제 전망
- 브라질
- 멕시코
- 기타
- 중동
- 아프리카
- 암 및 만성질환의 부담 증가가 성장을 촉진
- 아프리카의 거시경제 전망
제12장 경쟁 구도
- 서론
- 주요 참여 기업의 전략/강점
- 매출 분석, 2020-2024년
- 시장 점유율 분석, 2024년
- 기업 가치 평가와 재무 지표
- 브랜드/서비스 비교
- 기업 평가 매트릭스 : 주요 참여 기업, 2024년
- 기업 평가 매트릭스 : 스타트업/중소기업, 2024년
- 경쟁 시나리오
제13장 기업 개요
- 주요 참여 기업
- THERMO FISHER SCIENTIFIC INC.
- CHARLES RIVER LABORATORIES
- WUXI APPTEC
- PHARMARON
- LABCORP
- EVOTEC
- SYNGENE INTERNATIONAL LIMITED
- EUROFINS SCIENTIFIC
- JUBILANT PHARMOVA LIMITED
- GENSCRIPT
- FRONTAGE HOLDINGS CORPORATION
- PIRAMAL ENTERPRISES LTD.
- AURIGENE PHARMACEUTICAL SERVICES LTD.
- CURIA GLOBAL, INC.
- SHANGHAI MEDICILON INC.
- SYGNATURE DISCOVERY
- 기타 기업
- SELVITA
- VIVA BIOTECH
- TCG LIFESCIENCES PVT. LTD.
- SHANGHAI CHEMPARTNER
- DOMAINEX
- NUVISAN GMBH
- DALTON PHARMA SERVICES
- ARAGEN LIFE SCIENCES LTD.
- ONCODESIGN SERVICES
제14장 부록
KSA
The global drug discovery services market is anticipated to reach USD 27.23 billion in 2030 from USD 16.36 billion in 2025, with a significant CAGR of 10.7%. The market is growing strongly at a considerable CAGR due to rising R&D investments of pharmaceutical and biopharmaceutical firms. As the pipeline of R&D expands, the requirement for outsourcing analytical testing is set to rise, in addition to the research initiatives on the rare diseases and orphan drugs. Furthermore, the high costs of in-house drug development have also contributed to this trend. Industry players are likely to witness healthy growth opportunities due to the technological advancement, new drug discovery techniques, patent expiry, and rising demand for specialized testing services among end users.
| Scope of the Report |
|---|
| Years Considered for the Study | 2024-2030 |
| Base Year | 2024 |
| Forecast Period | 2024-2030 |
| Units Considered | Value (USD billion) |
| Segments | Products & Service, Application and End User |
| Regions covered | North America, Europe, Asia Pacific, Latin America, Middle East, and Africa |
"Chemistry services dominated the type segment"
Based on type, the drug discovery services market is divided into chemistry services, and biology services. The chemistry services segment is further divided into synthetic chemistry services, analytical chemistry services, other chemistry services. The development of technologies like combinatorial chemistry and structure-based drug design has contributed to the growth of chemistry services. Chemistry's extensive use in drug discovery particularly for lead molecule identification, lead modification or optimization, scale-up of the optimized lead for further drug development processes, and efficacy testing, has contributed to the growing demand for the segment.
"The hit-to-lead identification dominated the process segment"
Based on process, the drug discovery services market includes target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation. The hit-to-lead identification services dominated the market. Growth in the hit-to-lead identification services market is predetermined due to its crucial place in drug discovery, being the maximum revenue-generating process. Many CROs offer these services to pharmaceutical companies. Moreover, key players are focusing on improving this critical step of drug discovery.
"The small molecules dominated the drug type segment"
Based on drug type, the drug discovery services market can be segmented into small molecules, and biologics. Small molecules would hold largest share in the market. The increasing growth of the small molecules can be attributed to several factors such as ease of working with, low costs, and increasing startup and new entrants focusing on small-molecule drug development. Small molecules can also easily enter the cells thanks to their low molecular weights. They may act on other molecules and kill cancer cells. As such, small molecules or small-molecule inhibitors are used extensively for many targeted therapies.
"Cardiovascular diseases segment is anticipated to grow at a great pace"
The therapeutic area segment is divided into oncology, infectious diseases, cardiovascular diseases, neurological diseases, immunological disorders, endocrine & metabolic disorders, respiratory disorders, digestive system diseases, genitourinary diseases & women's health, and other therapeutic areas. The market for cardiovascular diseases is dominated due to high prevalence of cardiovascular diseases, rising geriatric population, and increasing partnerships between CROs and pharmaceutical & biotechnology companies. The integration of genetic and personalized medicine innovations will also support the growth of cardiovascular disease therapeutic discovery and development.
"Pharmaceutical & Biotechnology Companies dominated the segment"
Based on the end users, the market is segmented into pharmaceutical & biotechnology companies, academic institutes, and other end users. Pharmaceutical & biotechnology companies dominated the segment in 2024. The largest share of pharmaceutical and biotechnology companies in the drug discovery services market is due to the growing R&D expenditure for new molecules development, the increasing outsourcing of clinical services by these companies, and a strong pipeline of biotechnology companies to increase profit margins and reduce the time of drug development.
"US to grow at the highest CAGR for North America drug discovery services market"
The market is segmented by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America dominated the drug discovery services market in 2024 and is estimated to continue dominance during the forecast period. US leads the North American market, driven by the presence of key players. The country's focus on R&D expenditure, and rapid growth in the biosimilar and biologics markets further boosts its leadership in the market. European drug discovery services market is experiencing steady growth, supported by demographic changes, the growing prevalence of diseases, and investments in R&D.
In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the drug discovery services market.
The primary interviews conducted for this report can be categorized as follows:
- By Company Type: Tier 1 - 55%, Tier 2 - 25%, and Tier 3 - 20%
- By Designation: Directors - 45%, Managers - 30%, and Others - 25%
- By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%
Thermo Fisher Scientific Inc. (US), Labcorp (US), Eurofins Scientific (Germany), Charles River Laboratories (US), WuXi AppTec (China), Pharmaron (China), Evotec (Germany), Syngene International Limited (India), Curia Global, Inc. (US), Aragen Life Sciences Ltd. (India), Jubilant Pharmova Limited (India), Dr. Reddy's Laboratories Ltd. (India), Frontage Holdings Corporation (US), GenScript (US), Sygnature Discovery (UK), and Piramal Enterprises Ltd. (India) are some of the key players in the drug discovery services market.
Research Coverage:
Drug discovery services market report is segmented based on process (target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation), by type [(chemistry services (synthetic chemistry services, analytical chemistry services, other chemistry services), and biology services (in vitro profiling services, toxicology services, and other biology services)], by drug type (small molecules, and biologics), by therapeutic area (oncology, infectious diseases, cardiovascular diseases, neurological diseases, immunological disorders, endocrine & metabolic disorders, respiratory disorders, digestive system diseases, genitourinary diseases & women's health, and other therapeutic areas), by end user (pharmaceutical & biotechnology companies, academic institutes, and other end users), and region (North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the high content screening market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the high content screening market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the drug discovery services and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (Growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, Increasing demand for outsourcing analytical testing services, Initiatives for research on rare diseases and orphan drugs, High cost of in-house drug development), restraints (Stringent regulations governing drug discovery and animal usages), opportunities (Growth in drugs and biologics market, Rising demand for specialized testing services among end users, Patent Expiry, High growth prospect in emerging markets) and Challenges (Economic uncertainties worldwide) influencing the growth of the market.
- Product Development/Innovation: Detailed insights on upcoming technologies in drug discovery services, research and development activities, and new service launches in the drug discovery services market.
- Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the drug discovery services market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players Charles River Laboratories (US), Thermo Fisher Scientific Inc. (US), WuXi AppTec (China), and Pharmaron (China), and Labcorp (US), among others.
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 STUDY SCOPE
- 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
- 1.3.2 INCLUSIONS AND EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.4 CURRENCY CONSIDERED
- 1.5 STAKEHOLDERS
- 1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
- 2.1 RESEARCH DATA
- 2.1.1 SECONDARY DATA
- 2.1.1.1 Objectives of secondary research
- 2.1.2 PRIMARY DATA
- 2.1.2.1 Objectives of primary research
- 2.2 MARKET SIZE ESTIMATION
- 2.2.1 GLOBAL MARKET ESTIMATION
- 2.2.2 SEGMENTAL MARKET ESTIMATION
- 2.3 GROWTH RATE PROJECTIONS
- 2.4 DATA TRIANGULATION
- 2.5 RESEARCH ASSUMPTIONS
- 2.6 RESEARCH LIMITATIONS
- 2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
- 4.1 DRUG DISCOVERY SERVICES MARKET OVERVIEW
- 4.2 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE AND COUNTRY, 2024
- 4.3 DRUG DISCOVERY SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
- 4.4 DRUG DISCOVERY SERVICES MARKET, BY END USER
5 MARKET OVERVIEW
- 5.1 INTRODUCTION
- 5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
- 5.2.1.1 Booming research & development expenditure in pharma-biotech sector
- 5.2.1.2 Growing pipeline of pharmaceutical and biopharmaceutical companies
- 5.2.1.3 Rising research on rare diseases and orphan drugs
- 5.2.1.4 Increasing reliance on outsourcing due to costly in-house drug development
- 5.2.2 RESTRAINTS
- 5.2.2.1 Stringent regulations
- 5.2.3 OPPORTUNITIES
- 5.2.3.1 Technological advancements and new drug discovery techniques
- 5.2.3.2 Rising demand for specialized testing services
- 5.2.3.3 Patent expiry of key biologics
- 5.2.3.4 High growth prospects in emerging markets
- 5.2.4 CHALLENGES
- 5.2.4.1 Economic uncertainties worldwide
- 5.2.5 MARKET TRENDS
- 5.2.5.1 Adoption of AI in drug discovery
- 5.2.5.2 Increased outsourcing in emerging economies
- 5.2.5.3 Consolidation of contract research organizations
- 5.2.5.4 Integrated end-to-end R&D service offerings
- 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
- 5.4 PRICING ANALYSIS
- 5.4.1 INDICATIVE PRICING ANALYSIS OF DRUG DISCOVERY SERVICES, BY TYPE
- 5.4.2 INDICATIVE PRICING ANALYSIS OF DRUG DISCOVERY SERVICES, BY REGION
- 5.5 SUPPLY CHAIN ANALYSIS
- 5.6 VALUE CHAIN ANALYSIS
- 5.7 ECOSYSTEM ANALYSIS
- 5.8 INVESTMENT AND FUNDING SCENARIO
- 5.9 TECHNOLOGY ANALYSIS
- 5.9.1 KEY TECHNOLOGIES
- 5.9.1.1 High-throughput screening
- 5.9.1.2 CRISPR gene editing
- 5.9.1.3 Structure-based drug design/Computer-aided drug design
- 5.9.2 COMPLEMENTARY TECHNOLOGIES
- 5.9.2.1 Automated liquid handling
- 5.9.2.2 In silico modeling
- 5.9.2.3 Patient-derived xenografts and organoids
- 5.9.3 ADJACENT TECHNOLOGIES
- 5.9.3.1 Nanotechnology
- 5.9.3.2 Synthetic biology
- 5.9.3.3 Organ-on-a-chip technology
- 5.10 PATENT ANALYSIS
- 5.11 KEY CONFERENCES AND EVENTS, 2025-2026
- 5.12 REGULATORY LANDSCAPE
- 5.12.1 REGULATORY FRAMEWORK
- 5.12.1.1 North America
- 5.12.1.1.1 US
- 5.12.1.1.2 Canada
- 5.12.1.2 Europe
- 5.12.1.3 Asia Pacific
- 5.12.1.3.1 China
- 5.12.1.3.2 Japan
- 5.12.1.3.3 India
- 5.12.1.3.4 South Korea
- 5.12.1.3.5 Australia
- 5.12.1.3.6 Rest of Asia Pacific
- 5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 5.13 PORTER'S FIVE FORCES ANALYSIS
- 5.13.1 BARGAINING POWER OF SUPPLIERS
- 5.13.2 BARGAINING POWER OF BUYERS
- 5.13.3 THREAT OF NEW ENTRANTS
- 5.13.4 THREAT OF SUBSTITUTES
- 5.13.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
- 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 5.14.2 KEY BUYING CRITERIA, BY END USER
- 5.15 IMPACT OF AI ON DRUG DISCOVERY SERVICES MARKET
- 5.15.1 INTRODUCTION
- 5.15.2 MARKET POTENTIAL OF AI IN DRUG DISCOVERY SERVICES
- 5.15.3 AI USE CASES
- 5.15.4 FUTURE OF GENERATIVE AI IN DRUG DISCOVERY SERVICES MARKET
6 DRUG DISCOVERY SERVICES MARKET, BY PROCESS
- 6.1 INTRODUCTION
- 6.2 TARGET SELECTION
- 6.2.1 INCREASING FOCUS ON IDENTIFYING POTENTIAL DRUG TARGETS TO BOLSTER GROWTH
- 6.3 TARGET VALIDATION
- 6.3.1 INCREASING EMPHASIS ON AVOIDING LATE-STAGE FAILURE TO PROMOTE GROWTH
- 6.4 HIT-TO-LEAD IDENTIFICATION
- 6.4.1 RISING FOCUS ON DRUG DEVELOPMENT TO DRIVE MARKET
- 6.5 LEAD OPTIMIZATION
- 6.5.1 NEED FOR TRANSPARENT PRESENTATION AND ANALYSIS IN CLINICAL TRIALS TO STIMULATE GROWTH
- 6.6 CANDIDATE VALIDATION
- 6.6.1 GROWING ATTENTION ON POTENCY AND SPECIFICITY OF DRUGS TO BOOST MARKET
7 DRUG DISCOVERY SERVICES MARKET, BY TYPE
- 7.1 INTRODUCTION
- 7.2 CHEMISTRY SERVICES
- 7.2.1 SYNTHETIC CHEMISTRY SERVICES
- 7.2.1.1 Increasing reliance on novel and efficient synthetic routes to augment growth
- 7.2.2 ANALYTICAL CHEMISTRY SERVICES
- 7.2.2.1 Rising demand for high-quality, safe, and effective drugs to support growth
- 7.2.3 OTHER CHEMISTRY SERVICES
- 7.3 BIOLOGY SERVICES
- 7.3.1 IN VITRO PROFILING SERVICES
- 7.3.1.1 Need for higher project productivity to speed up growth
- 7.3.2 TOXICOLOGY SERVICES
- 7.3.2.1 Growing emphasis on assessing safety profiles of new drug candidates to propel market
- 7.3.3 OTHER BIOLOGY SERVICES
8 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE
- 8.1 INTRODUCTION
- 8.2 SMALL MOLECULES
- 8.2.1 INCREASING FOCUS ON OPTIMIZING SMALL-MOLECULE LEADS TO AMPLIFY GROWTH
- 8.3 BIOLOGICS
- 8.3.1 GROWING ADVANCEMENTS IN BIOTECHNOLOGY TO BOOST MARKET
9 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA
- 9.1 INTRODUCTION
- 9.2 ONCOLOGY
- 9.2.1 GROWING INCIDENCE OF CANCER TO PROPEL MARKET
- 9.3 INFECTIOUS DISEASES
- 9.3.1 RISING EPIDEMIC OUTBREAKS TO ASSIST GROWTH
- 9.4 CARDIOVASCULAR DISEASES
- 9.4.1 HIGH MORTALITY RATES TO SPUR GROWTH
- 9.5 NEUROLOGICAL DISEASES
- 9.5.1 INCREASING RESEARCH & DEVELOPMENT INVESTMENTS FOR NEUROLOGICAL DISORDERS TO FAVOR GROWTH
- 9.6 IMMUNOLOGICAL DISORDERS
- 9.6.1 GROWING DRUG PIPELINE FOR IMMUNOLOGICAL DISORDERS TO BOOST MARKET
- 9.7 ENDOCRINE & METABOLIC DISORDERS
- 9.7.1 BOOMING DIABETIC POPULATION TO AID GROWTH
- 9.8 RESPIRATORY DISORDERS
- 9.8.1 RISING BURDEN OF RESPIRATORY DISORDERS TO SUPPORT GROWTH
- 9.9 DIGESTIVE SYSTEM DISEASES
- 9.9.1 CHANGING LIFESTYLE AND DIETARY HABITS TO PROMOTE GROWTH
- 9.10 GENITOURINARY DISEASES & WOMEN'S HEALTH
- 9.10.1 RISING AWARENESS ABOUT EARLY DIAGNOSIS AND TREATMENT TO SUSTAIN GROWTH
- 9.11 OTHER THERAPEUTIC AREAS
10 DRUG DISCOVERY SERVICES MARKET, BY END USER
- 10.1 INTRODUCTION
- 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
- 10.2.1 TIER 1 COMPANIES
- 10.2.1.1 Rising research & development activities to sustain growth
- 10.2.2 TIER 2 COMPANIES
- 10.2.2.1 Growing focus on specific therapeutic areas to drive market
- 10.2.3 TIER 3 COMPANIES
- 10.2.3.1 Increasing specialized drug discovery projects to expedite growth
- 10.3 ACADEMIC INSTITUTES
- 10.3.1 INCREASING COLLABORATIONS AMONG MARKET PLAYERS TO CONTRIBUTE TO GROWTH
- 10.4 OTHER END USERS
11 DRUG DISCOVERY SERVICES MARKET, BY REGION
- 11.1 INTRODUCTION
- 11.2 NORTH AMERICA
- 11.2.1 MACROECONOMIC OUTLOOK OF NORTH AMERICA
- 11.2.2 US
- 11.2.2.1 Global leadership in pharmaceutical and biopharmaceutical research to aid growth
- 11.2.3 CANADA
- 11.2.3.1 Increasing initiatives for commercializing drugs to stimulate growth
- 11.3 EUROPE
- 11.3.1 MACROECONOMIC OUTLOOK OF EUROPE
- 11.3.2 GERMANY
- 11.3.2.1 Rising dominance of contract research organizations to encourage growth
- 11.3.3 UK
- 11.3.3.1 Increasing government-private sector collaborations to boost market
- 11.3.4 FRANCE
- 11.3.4.1 Growing number of oncology research projects to propel market
- 11.3.5 ITALY
- 11.3.5.1 High number of clinical trials and low drug approval time to promote growth
- 11.3.6 SPAIN
- 11.3.6.1 Rising elderly population to intensify growth
- 11.3.7 REST OF EUROPE
- 11.4 ASIA PACIFIC
- 11.4.1 MACROECONOMIC OUTLOOK OF ASIA PACIFIC
- 11.4.2 CHINA
- 11.4.2.1 Booming pharmaceutical industry to sustain growth
- 11.4.3 JAPAN
- 11.4.3.1 Increasing geriatric population to support growth
- 11.4.4 INDIA
- 11.4.4.1 Growing foreign direct investments to drive market
- 11.4.5 SOUTH KOREA
- 11.4.5.1 Favorable government support to accelerate growth
- 11.4.6 AUSTRALIA
- 11.4.6.1 Rising number of clinical trials to foster growth
- 11.4.7 REST OF ASIA PACIFIC
- 11.5 LATIN AMERICA
- 11.5.1 MACROECONOMIC OUTLOOK OF LATIN AMERICA
- 11.5.2 BRAZIL
- 11.5.2.1 Reduced timeline for drug approvals to favor growth
- 11.5.3 MEXICO
- 11.5.3.1 Favorable government policies to intensify growth
- 11.5.4 REST OF LATIN AMERICA
- 11.6 MIDDLE EAST
- 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
- 11.6.2 GCC COUNTRIES
- 11.6.2.1 Saudi Arabia
- 11.6.2.1.1 Booming healthcare expenditure to contribute to growth
- 11.6.2.2 UAE
- 11.6.2.2.1 Rising government initiatives for advanced healthcare to amplify growth
- 11.6.2.3 Other GCC Countries
- 11.6.3 REST OF MIDDLE EAST
- 11.7 AFRICA
- 11.7.1 RISING BURDEN OF CANCER AND CHRONIC DISEASES TO FACILITATE GROWTH
- 11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA
12 COMPETITIVE LANDSCAPE
- 12.1 INTRODUCTION
- 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
- 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DRUG DISCOVERY SERVICES MARKET
- 12.3 REVENUE ANALYSIS, 2020-2024
- 12.4 MARKET SHARE ANALYSIS, 2024
- 12.5 COMPANY VALUATION AND FINANCIAL METRICS
- 12.6 BRAND/SERVICE COMPARISON
- 12.6.1 THERMO FISHER SCIENTIFIC INC. (US)
- 12.6.2 CHARLES RIVER LABORATORIES (US)
- 12.6.3 LABCORP (US)
- 12.6.4 WUXI APPTEC (CHINA)
- 12.6.5 PHARMARON (CHINA)
- 12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
- 12.7.1 STARS
- 12.7.2 EMERGING LEADERS
- 12.7.3 PERVASIVE PLAYERS
- 12.7.4 PARTICIPANTS
- 12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
- 12.7.5.1 Company footprint
- 12.7.5.2 Region footprint
- 12.7.5.3 Process footprint
- 12.7.5.4 Type footprint
- 12.7.5.5 Therapeutic area footprint
- 12.7.5.6 Drug type footprint
- 12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
- 12.8.1 PROGRESSIVE COMPANIES
- 12.8.2 RESPONSIVE COMPANIES
- 12.8.3 DYNAMIC COMPANIES
- 12.8.4 STARTING BLOCKS
- 12.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES
- 12.8.5.1 Detailed list of key startups/SMEs
- 12.8.5.2 Competitive benchmarking of key startups/SMEs
- 12.9 COMPETITIVE SCENARIO
- 12.9.1 SERVICE LAUNCHES
- 12.9.2 DEALS
- 12.9.3 EXPANSIONS
- 12.9.4 OTHER DEVELOPMENTS
13 COMPANY PROFILES
- 13.1 KEY PLAYERS
- 13.1.1 THERMO FISHER SCIENTIFIC INC.
- 13.1.1.1 Business overview
- 13.1.1.2 Services offered
- 13.1.1.3 Recent developments
- 13.1.1.3.1 Service launches
- 13.1.1.3.2 Deals
- 13.1.1.3.3 Expansions
- 13.1.1.4 MnM view
- 13.1.1.4.1 Key strengths
- 13.1.1.4.2 Strategic choices
- 13.1.1.4.3 Weaknesses and competitive threats
- 13.1.2 CHARLES RIVER LABORATORIES
- 13.1.2.1 Business overview
- 13.1.2.2 Services offered
- 13.1.2.3 Recent developments
- 13.1.2.3.1 Service launches
- 13.1.2.3.2 Deals
- 13.1.2.4 MnM view
- 13.1.2.4.1 Key strengths
- 13.1.2.4.2 Strategic choices
- 13.1.2.4.3 Weaknesses and competitive threats
- 13.1.3 WUXI APPTEC
- 13.1.3.1 Business overview
- 13.1.3.2 Services offered
- 13.1.3.3 Recent developments
- 13.1.3.4 MnM view
- 13.1.3.4.1 Key strengths
- 13.1.3.4.2 Strategic choices
- 13.1.3.4.3 Weaknesses and competitive threats
- 13.1.4 PHARMARON
- 13.1.4.1 Business overview
- 13.1.4.2 Services offered
- 13.1.4.3 MnM view
- 13.1.4.3.1 Key strengths
- 13.1.4.3.2 Strategic choices
- 13.1.4.3.3 Weaknesses and competitive threats
- 13.1.5 LABCORP
- 13.1.5.1 Business overview
- 13.1.5.2 Services offered
- 13.1.5.3 Recent developments
- 13.1.5.3.1 Deals
- 13.1.5.3.2 Expansions
- 13.1.5.4 MnM view
- 13.1.5.4.1 Key strengths
- 13.1.5.4.2 Strategic choices
- 13.1.5.4.3 Weaknesses and competitive threats
- 13.1.6 EVOTEC
- 13.1.6.1 Business overview
- 13.1.6.2 Services offered
- 13.1.6.3 Recent developments
- 13.1.6.3.1 Deals
- 13.1.6.3.2 Expansions
- 13.1.6.3.3 Other developments
- 13.1.7 SYNGENE INTERNATIONAL LIMITED
- 13.1.7.1 Business overview
- 13.1.7.2 Services offered
- 13.1.7.3 Recent developments
- 13.1.7.3.1 Deals
- 13.1.7.3.2 Expansions
- 13.1.8 EUROFINS SCIENTIFIC
- 13.1.8.1 Business overview
- 13.1.8.2 Services offered
- 13.1.8.3 Recent developments
- 13.1.8.3.1 Service launches
- 13.1.8.3.2 Deals
- 13.1.8.3.3 Expansions
- 13.1.9 JUBILANT PHARMOVA LIMITED
- 13.1.9.1 Business overview
- 13.1.9.2 Services offered
- 13.1.9.3 Recent developments
- 13.1.9.3.1 Deals
- 13.1.9.3.2 Expansions
- 13.1.10 GENSCRIPT
- 13.1.10.1 Business overview
- 13.1.10.2 Services offered
- 13.1.10.3 Recent developments
- 13.1.10.3.1 Service launches
- 13.1.10.3.2 Deals
- 13.1.11 FRONTAGE HOLDINGS CORPORATION
- 13.1.11.1 Business overview
- 13.1.11.2 Services offered
- 13.1.11.3 Recent developments
- 13.1.11.3.1 Service launches
- 13.1.11.3.2 Deals
- 13.1.11.3.3 Expansions
- 13.1.12 PIRAMAL ENTERPRISES LTD.
- 13.1.12.1 Business overview
- 13.1.12.2 Services offered
- 13.1.12.3 Recent developments
- 13.1.13 AURIGENE PHARMACEUTICAL SERVICES LTD.
- 13.1.13.1 Business overview
- 13.1.13.2 Services offered
- 13.1.13.3 Recent developments
- 13.1.13.3.1 Service launches
- 13.1.13.3.2 Deals
- 13.1.13.3.3 Expansions
- 13.1.14 CURIA GLOBAL, INC.
- 13.1.14.1 Business overview
- 13.1.14.2 Services offered
- 13.1.14.3 Recent developments
- 13.1.14.3.1 Service launches
- 13.1.14.3.2 Deals
- 13.1.14.3.3 Other developments
- 13.1.15 SHANGHAI MEDICILON INC.
- 13.1.15.1 Business overview
- 13.1.15.2 Services offered
- 13.1.15.3 Recent developments
- 13.1.15.3.1 Deals
- 13.1.15.3.2 Expansions
- 13.1.16 SYGNATURE DISCOVERY
- 13.1.16.1 Business overview
- 13.1.16.2 Services offered
- 13.1.16.2.1 Deals
- 13.1.16.2.2 Expansions
- 13.2 OTHER PLAYERS
- 13.2.1 SELVITA
- 13.2.2 VIVA BIOTECH
- 13.2.3 TCG LIFESCIENCES PVT. LTD.
- 13.2.4 SHANGHAI CHEMPARTNER
- 13.2.5 DOMAINEX
- 13.2.6 NUVISAN GMBH
- 13.2.7 DALTON PHARMA SERVICES
- 13.2.8 ARAGEN LIFE SCIENCES LTD.
- 13.2.9 ONCODESIGN SERVICES
14 APPENDIX
- 14.1 DISCUSSION GUIDE
- 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 14.3 CUSTOMIZATION OPTIONS
- 14.4 RELATED REPORTS
- 14.5 AUTHOR DETAILS
